DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating
ConditionRenal Neoplasma
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-80
SponsorThe First People's Hospital of Changzhou
About this trial
The purpose of this study is to show if vaccination with autologous dendritic cells pulsed with tumor lysate in combination with Cytokine-Induced Killer Cell (CIK) can induce a measurable immune response in patients with renal cell carcinoma, and to evaluate the clinical effect of the regimen.
Eligibility criteria
Qualifiers
Histologically proven renal cell carcinoma
Age: > 18
WHO- ECOG Performance Status 0-1
At least one measurable tumor lesions according to the RECIST criteria.
Disqualifiers
Patients with a history of any other neoplastic disease less than 5 years ago (excepting treated carcinomas in situ of the cervix and basal/squamous cell carcinomas of the skin).
Patients with metastatic disease in the central nervous system (CNS).
Patients with other significant illness including severe allergy, asthma, angina pectoris or congestive heart failure.
Patients with acute or chronic infection including HIV.
Trial design
Treatments tested in this trial
- DC-CIK
- IL-2/IFN-α
Treatment groups
1,200 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov